BioCentury
ARTICLE | Company News

Lantibio Inc., TRB Chemedica International SA deal

January 16, 2006 8:00 AM UTC

TRB granted Lantibio exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio expects to begin "late stage" studies of the sodium hya...